• Wednesday, Jul 17, 2019
  • Last Update : 02:17 pm

Beximco Pharma begins exporting third product to the US market

  • Published at 10:18 pm April 24th, 2018
Beximco Pharma begins exporting third product to the US market
Beximco Pharma has began the export of their third product Methocarbamol (500mg and 700mg) to the US market on Tuesday. The first consignment was delivered on April 21, 2018 and this is the third product from Beximco Pharma in the world’s largest pharma market after the successful launch of Carvedilol and Sotalol in August 2016 and November 2017, respectively. Methocarbamol is generic equivalent to muscle relaxant drug Robaxin from Auxilium Pharmaceuticals. According to IQVIA market data, the US market for Methocarbamol is currently valued at USD 23.37 million. Beximco Pharma Managing Director Nazmul Hassan MP spoke on the occasion. Beximco Pharma remains the only Bangladeshi pharmaceutical company to export medicine to the US market following its manufacturing site approval by the US Food and Drug Administration in June 2015.